Lördag 21 December | 18:23:09 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-19 14:30 Kvartalsrapport 2025-Q2
2025-05-18 14:30 Kvartalsrapport 2025-Q1
2025-02-14 N/A Årsstämma
2025-02-14 15:00 Bokslutskommuniké 2024
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-31 - Årsstämma
2024-05-22 - Kvartalsrapport 2024-Q1
2024-05-17 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2024-02-14 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-26 - Årsstämma
2023-05-26 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-10-11 - Extra Bolagsstämma 2022
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-22 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2022-06-21 - Årsstämma
2022-05-27 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-09 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-06-22 - Årsstämma
2021-05-18 - Kvartalsrapport 2021-Q1

Beskrivning

LandFinland
ListaSpotlight
SektorHandel & varor
IndustriDetaljhandel
Eevia Health är verksamma inom life science. Bolaget erbjuder produktionsprotokoll och procedurer för att leverera ekologiska produkter till internationella kunder. Produkterna säljs till företagskunder och inkluderar ingredienser till producenter av kosttillskott, livsmedel och kosmetika på global basis. Produkterna innefattar exempelvis blåbär, chaga-svamp och tallbark. Eevia Health grundades 2017 och har sitt huvudkontor i Seinäjoki, Finland.
2024-10-30 07:30:00

Eevia Health Plc ("Eevia" or "The Company") has received a 51 KEUR sales order from a European nutraceutical brand owner.

The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements and cosmetics in over 50,000 pharmacies, health food shops, and other retail outlets across 38 countries, including China and the USA.

This new order's sales value to Eevia is c. 51 KEUR for Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins. This is a repeat order and one of the few brand holders of Eevia services without using a distributor. The business has developed, with repeat orders over the last few years. Eevia was selected due to its high quality and product authenticity.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.comorinvestor@eeviahealth.com

Telephone: +358400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name EEVIA (https://spotlightstockmarket.com/en/companies/irabout?InstrumentId=XSAT000085FD).

To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn @EeviaHealth.